Results 31 to 40 of about 14,917 (287)
Edaravone May Prevent Ferroptosis in ALS [PDF]
Current Drug Targets, 2020 Radicava™ (Edaravone) was approved the Food and Drug Administration (FDA) as a new treatment for amyotrophic lateral sclerosis (ALS). Edaravone is a synthetic antioxidant that specifically targets oxidative damage interacting with lipid radicals in the cell.
Snežana Spasić +6 more
openaire +5 more sources
Post-ischaemic immunological response in the brain: targeting microglia in ischaemic stroke therapy [PDF]
, 2020 Microglia, the major endogenous immune cells of the central nervous system, mediate critical degenerative and regenerative responses in ischaemic stroke.
Chen, Ruoli +4 more
core +3 more sources
Edaravone attenuates sustained pial arteriolar vasoconstriction independently of endothelial function after unclamping of the abdominal aorta in rabbits [PDF]
Korean Journal of Anesthesiology, 2021 Background Cerebral blood flow (CBF) has direct effects on neuronal function and neurocognitive disorders. Oxidative stress from abdominal aortic surgery is important in the pathophysiology of CBF impairment.
Tomohiro Michino +6 more
doaj +1 more source
Pharmaceutics, 2021 Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one) is a free radical scavenger approved for the treatment of amyotrophic lateral sclerosis, a fatal neuromuscular disease. Edaravone is administered as an intravenous infusion over 60 min for several treatment
Dong Wook Kang +9 more
doaj +1 more source
A staged screening of registered drugs highlights remyelinating drug candidates for clinical trials [PDF]
, 2017 There is no treatment for the myelin loss in multiple sclerosis, ultimately resulting in the axonal degeneration that leads to the progressive phase of the disease.
Agresti, C. +11 more
core +2 more sources
Cureus, 2023 The use of Edaravone, given orally, for the treatment of amyotrophic lateral sclerosis (ALS) was officially approved by the Federal Drug Association (FDA) in 2017. ALS is a rare and progressive degenerative disease that worsens over time.
P. Neupane +9 more
semanticscholar +1 more source
Edaravone, a potent free radical scavenger, reacts with peroxynitrite to produce predominantly 4-NO-edaravone [PDF]
Redox Report, 2016 3-Methyl-1-phenyl-2-pyrazolin-5-one (edaravone) is used in clinical treatment of acute brain infarction to rescue the penumbra, based on its ability to prevent lipid peroxidation by scavenging lipid peroxyl radicals. Here, we show that edaravone also reacts with peroxynitrite to yield 4-NO-edaravone as the major product and 4-NO2-edaravone as a minor ...
Yorihiro Yamamoto, Akio Fujisawa
openaire +2 more sources
Turkish Journal of Vascular Surgery, 2023 Aim: Lower limb ischemia/reperfusion leads to distant organ dysfunction, notably affecting the lungs, resulting in respiratory failure and significant morbidity and mortality.
Mehmet Ceber +4 more
doaj +1 more source
Oral Edaravone – Introducing a Flexible Treatment Option for Amyotrophic Lateral Sclerosis
Expert Review of Neurotherapeutics, 2023 Introduction Amyotrophic lateral sclerosis (ALS) is a progressive and incurable neurodegenerative disease. While pharmacotherapy options remain limited, the Food and Drug Administration (FDA) approved intravenous (IV) and oral edaravone for the treatment
G. Pattee +10 more
semanticscholar +1 more source
Application of a free radical scavenger edaravone in patients with hemorrhagic stroke
Infusion & Chemotherapy, 2021 BACKGROUND. The free radical scavenger edaravone helps to reduce the area of ischemic injury and improve the longterm effects of stroke, and is therefore widely used in the treatment of ischemic stroke.
O.A. Halushko
doaj +1 more source